| abstract |
ERYTHROPOIETIN VARIANTS. The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for the treatment or prevention of a condition associated with tissue damage caused by cell death (apoptosis, necrosis) and inflammation, particularly for neuroprotection, e.g. treatment of acute (e.g. stroke) and chronic (e.g. ALS) disease of the nervous system. |